The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

Stocks•1 May 2026•

1 min read

Standex International Shares Drop Despite Adjusted Earnings Growth in Q3

Key Facts

1Standex International reported growth in adjusted EPS and net profits for Q3 FY2026.

2Headline earnings were inflated by a one-time $56.8 million gain from a business sale.

3The Scientific segment lagged due to NIH funding cuts.

Standex International shares experienced a significant decline following the release of its Q3 FY2026 financial results, despite reporting growth in adjusted EPS and net income. Headline earnings were notably inflated by a one-time gain of $56.8 million stemming from a business divestiture, which raised questions regarding underlying organic growth. The company's Scientific segment faced headwinds due to funding cuts from the National Institutes of Health (NIH), dragging down overall performance. Analysts attributed the share price drop to valuation concerns and a slight miss on revenue expectations. While sectors like Electronics and Aerospace showed resilience, the market reacted negatively to the skewed earnings profile. Investors remain cautious as the company navigates shifting government funding landscapes and integration of its core business units.